ABOS
Acumen Pharmaceuticals Inc
2.00$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Acumen Pharmaceuticals Inc (ABOS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -18 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.8 | -1.5 | -1.3 | -2.9 | -2.4 | -4.3 | -7.7 | -3.6 | -8.3 | -6.5 | -9.2 | -11 | -10 | -12 | -13 | -8.3 | -18 | -17 | -25 | -27 | -34 | -32 | -30 | -19 | -24 | -18 | -92 | |
| – | – | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | -0.2 | 0.6 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.3 | 0.4 | 0.6 | 0.7 | 0.8 | 0.9 | 1.4 | 1.5 | 1.6 | 1.6 | 2.5 | 2.5 | 2.3 | 2.3 | 2.5 | 2.5 | 2.5 | 2.4 | 2.4 | 2.5 | 9.8 | |
| 0.0 | 0.0 | 0.0 | – | 23 | 58 | 0.3 | 0.6 | 0.6 | 0.7 | 1.0 | 0.9 | 1.4 | 1.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.2 | 0.5 | 1.2 | -1.6 | 1.3 | -1.0 | -4.1 | 4.1 | 0.0 | 2.8 | 0.5 | 0.8 | 0.0 | -1.3 | -0.9 | 6.1 | -4.1 | 3.8 | 3.7 | 8.2 | -7.4 | 6.3 | -7.0 | 3.0 | -5.7 | 12 | 2.0 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | -94 | -10 | -5.1 | 8.8 | 56 | -20 | -42 | 11 | -92 | -49 | -9.2 | 38 | -10 | 30 | 29 | 38 | 41 | 26 | -14 | 26 | 79 | |
| – | – | – | – | – | – | – | – | – | 0.0 | -0.3 | 4.2 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | -0.3 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | |
| 32 | 32 | 32 | 45 | 32 | 32 | 169 | 0.0 | 0.0 | 0.0 | -0.3 | 4.2 | -0.1 | -0.1 | 123 | 29 | 7.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 36 | -0.3 | 35 | |
| -1.8 | -1.5 | -1.3 | 42 | -2.4 | 27 | 67 | -14 | -13 | 2.3 | 46 | -27 | -52 | -0.8 | 18 | -28 | -20 | 21 | -35 | 2.4 | -5.5 | 6.7 | 10 | 7.2 | -2.2 | 7.6 | 23 | |
| -1.8 | -1.5 | -1.3 | -2.9 | -2.4 | -4.3 | -7.7 | -3.7 | -8.3 | -6.5 | -9.3 | -11 | -10 | -12 | -13 | -8.3 | -18 | -17 | -25 | -27 | -34 | -32 | -30 | -19 | -24 | -18 | -92 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.